The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

During tumorigenesis, cancer cells are exposed to a wide variety of intrinsic and extrinsic
stresses that challenge homeostasis and growth. Cancer cells display activation of distinct …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Pyroptosis, a form of programmed cell death, has garnered increasing attention as it relates
to innate immunity and diseases. The discovery of caspase-1/3/4/5/8/11 function in sensing …

Nextgeneration sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide
clinical management by providing information about actionable gene aberrations that have …

The'hallmarks of cancer'are generally accepted as a set of genetic and epigenetic
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …